Acrobiosystems Co

Acrobiosystems Co CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Acrobiosystems Co (301080.SZ) as of Oct 16, 2026 is 57.65 %. In the previous year, CapEx to Operating Cash Flow Ratio was 197.46 % — a change of -70.80% (lower).

CapEx/OCF

57.65 %

YoY

-70.80%

Last updated:

CapEx to Operating Cash Flow Ratio of Acrobiosystems Co is 2025 57.65 % . CapEx to Operating Cash Flow Ratio of Acrobiosystems Co was 2024 197.46 % . It decreases by -70.80% lower compared to the previous year.

The Acrobiosystems Co CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
134.44 CNY
Jan 1, 2019
49.47 CNY
Jan 1, 2020
15.52 CNY
Jan 1, 2021
44.68 CNY
Jan 1, 2022
140.61 CNY
Jan 1, 2023
115.73 CNY
Jan 1, 2024
197.46 CNY
Jan 1, 2025
57.65 CNY
The Acrobiosystems Co CapEx/OCF history
YEARCapEx/OCFYoY
57.65 %-70.80%
197.46 %+70.62%
115.73 %-17.69%
140.61 %+214.72%
44.68 %+187.78%
15.52 %-68.62%
49.47 %-63.20%
134.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd is a biotechnology company based in Beijing, China, operating within the Health Care sector. The company specializes in the development of biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, and related products such as kits, antibodies, fillers, and culture media. With 597 full-time employees, Acrobiosystems provides services and products primarily for research and development (R&D) and production processes in the pharmaceutical and biotechnology industries. Its offerings support early drug discovery, verification, drug screening, optimization, diagnostic reagent development, and preclinical and clinical trials for various diseases, including tumors, autoimmune disorders, cardiovascular conditions, and infectious diseases. The company completed its initial public offering (IPO) on October 18, 2021, and is listed under the ticker symbol 301080.SZ with ISIN CNE100004S13. Acrobiosystems operates from its headquarters in Beijing, leveraging its technological expertise to contribute to advancements in drug development and diagnostic solutions. The company's website is https://www.acrobiosystems.cn/. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

CapEx to Operating Cash Flow Ratio of Acrobiosystems Co is 57.65 % in 2025.

CapEx to Operating Cash Flow Ratio of Acrobiosystems Co changed from 197.46 % to 57.65 %, representing a -70.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co